CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Accumulating evidence indicates that CD8(+) T cells in the tumor microenvironment and systemic CD4(+) T-cell immunity play an important role in mediating durable antitumor responses. We longitudinally examined T-cell immunity in the peripheral blood of patients with non-small lung cancer and found that responders had significantly (P < 0.0001) higher percentages of effector, CD62L(low) CD4(+) T cells prior to PD-1 blockade. Conversely, the percentage of CD25(+) FOXP3(+) CD4(+) T cells was significantly (P = 0.034) higher in nonresponders. We developed a formula, which demonstrated 85.7% sensitivity and 100% specificity, based on the percentages of CD62L(low) CD4(+) T cells and CD25(+)FOXP3(+) cells to predict nonresponders. Mass cytometry analysis revealed that the CD62L(low) CD4(+) T-cell subset expressed T-bet(+), CD27(-), FOXP3(-), and CXCR3(+), indicative of a Th1 subpopulation. CD62L(low) CD4(+) T cells significantly correlated with effector CD8(+) T cells (P = 0.0091) and with PD-1 expression on effector CD8(+) T cells (P = 0.0015). Gene expression analysis revealed that CCL19, CLEC-2A, IFNA, IL7, TGFBR3, CXCR3, and HDAC9 were preferentially expressed in CD62L(low) CD4(+) T cells derived from responders. Notably, long-term responders, who had >500-day progression-free survival, showed significantly higher numbers of CD62L(low) CD4(+) T cells prior to PD-1 blockade therapy. Decreased CD62L(low) CD4(+) T-cell percentages after therapy resulted in acquired resistance, with long-term survivors maintaining high CD62L(low) CD4(+) T-cell percentages. These results pave the way for new treatment strategies for patients by monitoring CD4(+) T-cell immune statuses in their peripheral blood.